Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

Clinical Pharmacology and Therapeutics
Daniel J CronaYoung E Whang

Abstract

Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms of resistance include the following: 1) Expression of AR splice variants, such as the AR-V7 isoform, which lacks the ligand-binding domain; 2) AR missense mutations in the ligand-binding domain, such as F876L and T877A; and 3) Mutation or overexpression of androgen biosynthetic enzymes or glucocorticoid receptor. Several novel agents may overcome resistance mechanisms. Galeterone acts through multiple mechanisms that include degradation of AR protein and is being evaluated in CRPC patients positive for AR-V7. EPI-001 and related compounds inhibit AR splice variants by targeting the N-terminal transactivation domain of AR. Promising therapies and novel biomarkers, such as AR-V7, may lead to improved outcomes for CRPC patients.

References

Mar 20, 2002·Nature Reviews. Cancer·B J Feldman, D Feldman
May 23, 2002·CA: a Cancer Journal for Clinicians·Beth A Hellerstedt, Kenneth J Pienta
Jun 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward P Gelmann
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary-Ellen TaplinUNKNOWN Cancer and Leukemia Group B Study 9663
Jan 2, 2004·Nature Medicine·Charlie D ChenCharles L Sawyers
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I Scher, Charles L Sawyers
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhardt AttardJohann S de Bono
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhardt AttardJohann S de Bono
Feb 9, 2010·Trends in Endocrinology and Metabolism : TEM·Karen E Knudsen, Trevor M Penning
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J RyanEric J Small
Apr 20, 2010·Lancet·Howard I ScherUNKNOWN Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
Jul 21, 2010·The Journal of Clinical Investigation·Shihua SunStephen R Plymate
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Nov 15, 2011·The Journal of Urology·Patrick C Walsh
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter S Nelson
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleni EfstathiouChristopher J Logothetis
Jan 24, 2012·Cancer Research·Nicola J CleggJeffrey H Hager
Feb 14, 2012·Journal of Cell Science·Martin E van RoyenJan Trapman
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Oct 31, 2012·Cancer Treatment Reviews·Stéphane Oudard
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K L NoonanK N Chi
Jun 1, 2013·The Journal of Clinical Investigation·Jae-Kyung MyungMarianne D Sadar
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators
Aug 13, 2013·The Journal of Urology·Samir S Taneja

❮ Previous
Next ❯

Citations

Feb 2, 2016·Cancer Treatment Reviews·Chiara CiccareseFrancesco Massari
Jan 16, 2016·Clinical Pharmacology and Therapeutics·M F Paine, B P Smith
Apr 5, 2016·Medical Oncology·Laura Graham, Michael T Schweizer
Apr 9, 2017·Cellular Signalling·Wei ChenJiangbo Wang
May 12, 2017·Expert Opinion on Pharmacotherapy·Neal D Shore
Jun 2, 2018·Expert Opinion on Investigational Drugs·Athanasios E Dellis, Athanasios G Papatsoris
Nov 22, 2018·Expert Opinion on Pharmacotherapy·Athanasios E Dellis, Athanasios G Papatsoris
Jan 15, 2019·Endocrine Connections·Michael UlmRamesh Narayanan
Mar 1, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Takayuki AraiNaohiko Seki
Sep 13, 2019·Nature Reviews. Cancer·John H Bushweller
Nov 13, 2019·Nature Reviews. Urology·Michael J MorrisGeorge Sgouros
May 7, 2020·Molecular Cancer Therapeutics·Remi Adelaiye-OgalaDavid J VanderWeele
Sep 7, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rayna RosatiManohar Ratnam
Aug 19, 2017·Cancer Research·Lin WangBo Han
Nov 3, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
Oct 3, 2018·The American Journal of Pathology·Riikka HuhtaniemiMatti Poutanen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.